Pharmacological Prevention of Ectopic Erythrophagocytosis by Cilostazol Mitigates Ferroptosis in NASH

Hepatic iron overload (HIO) is a hallmark of nonalcoholic fatty liver disease (NAFLD) with a poor prognosis. Recently, the role of hepatic erythrophagocytosis in NAFLD is emerging as a cause of HIO. We undertook various assays using human NAFLD patient pathology samples and an in vivo nonalcoholic steatohepatitis (NASH) mouse model named STAMTM. To make the in vitro conditions comparable to those of the in vivo NASH model, red blood cells (RBCs) and platelets were suspended and subjected to metabolic and inflammatory stresses. An insert-coculture system, in which activated THP-1 cells and RBCs are separated from HepG2 cells by a porous membrane, was also employed. Through various analyses in this study, the effect of cilostazol was examined. The NAFLD activity score, including steatosis, ballooning degeneration, inflammation, and fibrosis, was increased in STAMTM mice. Importantly, hemolysis occurred in the serum of STAMTM mice. Although cilostazol did not improve lipid or glucose profiles, it ameliorated hepatic steatosis and inflammation in STAMTM mice. Platelets (PLTs) played an important role in increasing erythrophagocytosis in the NASH liver. Upregulated erythrophagocytosis drives cells into ferroptosis, resulting in liver cell death. Cilostazol inhibited the augmentation of PLT and RBC accumulation. Cilostazol prevented the PLT-induced increase in ectopic erythrophagocytosis in in vivo and in vitro NASH models. Cilostazol attenuated ferroptosis of hepatocytes and phagocytosis of RBCs by THP-1 cells. Augmentation of hepatic erythrophagocytosis by activated platelets in NASH exacerbates HIO. Cilostazol prevents ectopic erythrophagocytosis, mitigating HIO-mediated ferroptosis in NASH models.

[1]  Y. Yoo,et al.  Hepatic STAMP2 alleviates polychlorinated biphenyl‐induced steatosis and hepatic iron overload in NAFLD models , 2022, Environmental toxicology.

[2]  Ming Yan,et al.  Loss of hepatic Flcn protects against fibrosis and inflammation by activating autophagy pathways , 2021, Scientific Reports.

[3]  Y. Birnbaum,et al.  Cilostazol: a Review of Basic Mechanisms and Clinical Uses , 2021, Cardiovascular Drugs and Therapy.

[4]  Y. Yoo,et al.  Hepatic STAMP2 mediates recombinant FGF21‐induced improvement of hepatic iron overload in nonalcoholic fatty liver disease , 2020, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[5]  G. Birk,et al.  Deep learning enables pathologist-like scoring of NASH models , 2019, Scientific Reports.

[6]  J. Bosch,et al.  New Rat Model of Advanced NASH Mimicking Pathophysiological Features and Transcriptomic Signature of The Human Disease , 2019, Cells.

[7]  T. Greten,et al.  The effects of platelet accumulation in fatty liver disease , 2019, Nature Reviews Gastroenterology & Hepatology.

[8]  J. Jelsing,et al.  Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals. , 2019, American journal of physiology. Gastrointestinal and liver physiology.

[9]  D. Tang,et al.  The release and activity of HMGB1 in ferroptosis. , 2019, Biochemical and biophysical research communications.

[10]  Z. Younossi Non-alcoholic fatty liver disease - A global public health perspective. , 2019, Journal of hepatology.

[11]  Caroline L. Wilson,et al.  Platelet GPIbα is a mediator and potential interventional target for NASH and subsequent liver cancer , 2019, Nature Medicine.

[12]  Y. Yoo,et al.  Cilostazol Improves HFD-Induced Hepatic Steatosis by Upregulating Hepatic STAMP2 Expression through AMPK , 2018, Molecular Pharmacology.

[13]  C. McClain,et al.  Role of cAMP and phosphodiesterase signaling in liver health and disease. , 2018, Cellular signalling.

[14]  N. S. Gowert,et al.  Platelet-RBC interaction mediated by FasL/FasR induces procoagulant activity important for thrombosis , 2018, The Journal of clinical investigation.

[15]  Hong Chen,et al.  Pathogenesis of non-alcoholic fatty liver disease in children and adolescence: From “two hit theory” to “multiple hit model” , 2018, World journal of gastroenterology.

[16]  R. Weissleder,et al.  On-demand erythrocyte disposal and iron recycling requires transient macrophages in the liver , 2016, Nature Medicine.

[17]  D. Tang,et al.  Ferroptosis: process and function , 2016, Cell Death and Differentiation.

[18]  H. Cortez‐Pinto,et al.  Necroptosis is a key pathogenic event in human and experimental murine models of non-alcoholic steatohepatitis. , 2015, Clinical science.

[19]  S. Meuth,et al.  Platelets induce apoptosis via membrane-bound FasL. , 2015, Blood.

[20]  J. Balla,et al.  Red blood cell, hemoglobin and heme in the progression of atherosclerosis , 2014, Front. Physiol..

[21]  Fernando A Bozza,et al.  Platelet Activation and Apoptosis Modulate Monocyte Inflammatory Responses in Dengue , 2014, The Journal of Immunology.

[22]  A. Wree,et al.  Biomarkers of liver cell death. , 2014, Journal of hepatology.

[23]  P. Kubes,et al.  Nucleation of platelets with bloodborne pathogens on Kupffer cell precedes other innate immunity and contributes to bacterial clearance , 2013, Nature Immunology.

[24]  Kenji Suzuki,et al.  A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma , 2013, Medical Molecular Morphology.

[25]  M. Garrick,et al.  Heme carrier protein 1 transports heme and is involved in heme-Fe metabolism. , 2012, American journal of physiology. Cell physiology.

[26]  A. Feldstein,et al.  Mean platelet volume as a marker of increased cardiovascular risk in patients with nonalcoholic steatohepatitis , 2012, Hepatology.

[27]  L. N. Valenti,et al.  Iron in fatty liver and in the metabolic syndrome: a promising therapeutic target. , 2011, Journal of hepatology.

[28]  T. Saibara,et al.  Platelet count for predicting fibrosis in nonalcoholic fatty liver disease , 2011, Journal of Gastroenterology.

[29]  Florian Lang,et al.  Erythrocyte programmed cell death , 2008, IUBMB life.

[30]  H. Kirikoshi,et al.  Effectiveness of antiplatelet drugs against experimental non-alcoholic fatty liver disease , 2008, Gut.

[31]  T. Arakawa,et al.  Erythrophagocytosis by liver macrophages (Kupffer cells) promotes oxidative stress, inflammation, and fibrosis in a rabbit model of steatohepatitis: implications for the pathogenesis of human nonalcoholic steatohepatitis. , 2007, The American journal of pathology.

[32]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[33]  Renu Virmani,et al.  Intraplaque hemorrhage and progression of coronary atheroma. , 2003, The New England journal of medicine.